How Analysts Feel About Glaukos Corporation (NYSE:GKOS) After Increase in Sellers?

May 6, 2018 - By Vivian Currie

Glaukos Corporation (NYSE:GKOS) Logo

The stock of Glaukos Corporation (NYSE:GKOS) registered an increase of 18.29% in short interest. GKOS’s total short interest was 5.26M shares in May as published by FINRA. Its up 18.29% from 4.45M shares, reported previously. With 791,300 shares average volume, it will take short sellers 7 days to cover their GKOS’s short positions. The short interest to Glaukos Corporation’s float is 17.18%.

The stock decreased 1.57% or $0.55 during the last trading session, reaching $34.45. About 321,389 shares traded. Glaukos Corporation (NYSE:GKOS) has declined 40.30% since May 6, 2017 and is downtrending. It has underperformed by 51.85% the S&P500.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. The company has market cap of $1.20 billion. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. It currently has negative earnings. The companyÂ’s product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.

Glaukos Corporation (NYSE:GKOS) Ratings Coverage

Among 7 analysts covering Glaukos (NYSE:GKOS), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Glaukos had 14 analyst reports since November 8, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, February 26 by Stifel Nicolaus. On Thursday, November 16 the stock rating was maintained by BMO Capital Markets with “Outperform”. Cantor Fitzgerald maintained it with “Buy” rating and $48.0 target in Wednesday, December 27 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, January 10. The firm has “Buy” rating by Wells Fargo given on Tuesday, December 12. Stephens maintained the shares of GKOS in report on Thursday, March 1 with “Buy” rating. The stock has “Outperform” rating by BMO Capital Markets on Thursday, March 1. On Friday, February 23 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, November 7. The stock has “Buy” rating by Piper Jaffray on Wednesday, January 10.

Glaukos Corporation (NYSE:GKOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: